January 6, 2014 -- TaiGen Biotechnology of Taiwan will launch its first product, a novel antibiotic, in China in the second half of 2014, according to the company’s Chairman and CEO, Ming-chu Hsu. Nemonoxacin is a treatment for pneumonia and skin infections. TaiGen sold China rights for nemonoxacin to Zhejiang Medicine Co. in 2012 for $8 million upfront. Approval of the antibiotic in Taiwan should follow in 2015, said the company. More details....